Onglyza makes it to FDA, but will it make it through?
This article was originally published in Pharmaceutical Approvals Monthly
Bristol-Myers Squibb and AstraZeneca submitted their type 2 diabetes drug Onglyza (saxagliptin) to FDA on June 30 and to European regulators on July 1, the firms announce July 23. Approval would make it the second or third DPP-4 inhibitor on the U.S. market (Merck's Januvia was approved in 2006 and Takeda submitted alogliptin in late December 2007), but the timing may not be right for an easy diabetes approval. Due to concerns about cardiovascular safety with type 2 diabetes therapies, FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted at its July 2 meeting to tighten cardiovascular review for such medications, and FDA is grappling with how to put that into practice
You may also be interested in...
COVID-19 has disrupted the operational schedules of health care and technology providers alike to unparalleled levels in 2020. But scratch the surface, and outcomes-oriented, value-based health care targets remains a priority – albeit competing a little harder for attention at present.
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
Kim Trautman, who authored the US FDA’s Quality System Regulation in the 1990s, tells Medtech Insight that the agency probably won’t release a draft of its updated, harmonized QSR until next year thanks in part to a recent move by HHS secretary Alex Azar to personally sign off on every rule.